CRMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CorMedix Inc (CRMD) does not currently present a strong buy opportunity for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has shown significant revenue growth, other financial metrics, technical indicators, and lack of strong trading signals suggest a cautious approach. Holding the stock or waiting for better entry points is recommended.
The MACD is positive and expanding, indicating a bullish momentum. However, the RSI is neutral at 64.807, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance levels (R1: 6.689, R2: 6.83), suggesting limited immediate upside.
Revenue increased significantly by 312.10% YoY in Q4 2025, and the net income also grew by 4.13% YoY. Analysts maintain Outperform and Buy ratings, with a price target of $13, indicating potential upside.
EPS dropped by -31.82% YoY, and gross margin declined by -13.30% YoY. Analysts have lowered price targets recently, reflecting reduced expectations. No recent news or congress trading data to provide additional positive sentiment.
In Q4 2025, revenue increased by 312.10% YoY to $128.6M, and net income rose by 4.13% YoY to $14M. However, EPS dropped by -31.82% YoY to 0.15, and gross margin fell to 83.43%, down -13.30% YoY.
Analysts have lowered price targets recently but maintain Outperform and Buy ratings. The current price target is $13, down from previous targets of $15-$22, reflecting reduced expectations for the company's future performance.
